At what enterprise value was NEOPHARMED GENTILI acquired in 2018?

You can find the full valuation details of NEOPHARMED GENTILI on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of NEOPHARMED GENTILI when it was acquired by ARDIAN?

The exact EV/EBITDA multiple for NEOPHARMED GENTILI is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was NEOPHARMED GENTILI acquired by ARDIAN?

NEOPHARMED GENTILI was acquired by ARDIAN in 2018.

What was the revenue of NEOPHARMED GENTILI at the time of the deal?

The revenue of NEOPHARMED GENTILI at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of NEOPHARMED GENTILI during the acquisition?

NEOPHARMED GENTILI's EBITDA is estimated to be in the range of 50M - 100M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the NEOPHARMED GENTILI acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the NEOPHARMED GENTILI deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.ardian.com/fr/communiques-de-presse/ardian-acquiert-une-participation-majoritaire-dans-neopharmed-gentili

← DATABASE

Home Database Healthcare & PharmaNEOPHARMED GENTILI

11/2018

NEOPHARMED GENTILI acquired by ARDIAN

ITALY Life Sciences / Pharma & Biotech / Generics / Labs REV 100M - 200M EUR

Context

Ardian acquired a majority stake in Neopharmed Gentili from its founding parent company, Mediolanum Farmaceutici. The Del Bono family, founders of Mediolanum, retained a 20% minority stake in the business to ensure operational and clinical continuity. The transaction was structured to provide the group with the capital and global network necessary to transition from a national champion to an international specialty pharma platform. The investment thesis centered on using Neopharmed's robust Italian sales network as a foundation for an aggressive "buy-and-build" strategy, targeting both product portfolios and strategic corporate acquisitions across Europe.

NEOPHARMED GENTILI, which reported an EBITDA margin of in 2017, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Neopharmed Gentili is a leading Italian pharmaceutical company specialized in the development, production, and marketing of high-quality therapeutic treatments. It holds a dominant position in the Italian market for vascular, cardio-metabolic, and respiratory diseases, as well as anti-infectives and over-the-counter (OTC) products. The group acts as a key partner for global pharma giants like Merck and Teva, managing licensed portfolios alongside its own proprietary brands.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2017

2016

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
04/2019	ICG / MERIEUX EQUITY PARTNERS	DOC GENERICI	ITALY	Generics / Labs
12/2018	MERCK & CO.	ANTELLIQ	FRANCE	Animal Health
10/2018	ARDIAN	INULA GROUP	BELGIUM	Pharma & Biotech
10/2018	BRIDGEPOINT	HTL BIOTECHNOLOGY	FRANCE	CDMO
10/2018	ASTORG	NEMERA	FRANCE	Medical Consumables
08/2018	DENTRESSANGLE	ACTEON	FRANCE	Medical Devices
05/2018	Zoetis	Abaxis	UNITED STATES	Diagnostic Equipment
05/2018	NN	PARAGON MEDICAL	UNITED STATES	Medical Devices
05/2018	PERMIRA	CORIN GROUP	UNITED KINGDOM	Implants & Prosthetics
12/2017	PERKINELMER	EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS	GERMANY	Diagnostic Equipment

REFERENCES

Revenue range: 100M - 200M EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NEOPHARMED GENTILI by ARDIAN are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: ardian